• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Baxter BioPharma Solutions

    Syngene

    Almac Group

    Aphena Pharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Almac Group

    Reed-Lane

    Alcami

    Syngene
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    CEO Spotlight: Dr. Tae Han Kim

    Samsung Biologics’ chief executive talks biopharma outsourcing trends, company growth initiatives and the impact of the coronavirus pandemic

    CEO Spotlight: Dr. Tae Han Kim
    Tim Wright, Editor, Contract Pharma05.05.20
    It has been nearly 10 years since Samsung Biologics began operations as a full-service provider of cGMP contract manufacturing for the global biopharmaceutical industry. In that time, the Incheon, South Korea-based company has grown to become one of the top global contract service providers in the biopharma industry. Its facilities produce monoclonal and recombinant drug substance and drug product, and integrated services include cell line generation, process development, analytical services, clinical and commercial bulk cGMP manufacturing and fill finish services.

    Back in 2011, Dr. Tae Han Kim obtained approval from the Samsung Group to start Samsung Biologics as a new growth engine, building upon the success of Samsung’s engineering, construction, and clean room operations. He has since been at the helm as the founding chief executive officer. During his tenure as CEO, the company has grown from 30 people to over 3,000 as of 2020, and supports the world’s largest biologics manufacturing capacity from a single location.

    Dr. Kim’s career with Samsung spans over four decades. During this time, he has played an instrumental role not only in the biopharmaceutical industry but also in several other fields. After obtaining multiple advanced degrees in chemical engineering from the University of Texas at Austin, Dr. Kim began to take on various leadership roles at Samsung. Before starting Samsung Biologics, he served as vice president at Samsung General Chemical, senior vice president at Samsung Total, and executive vice president at Samsung Electronics.

    Contract Pharma recently had the opportunity to discuss with Dr. Kim the state of biopharma outsourcing, Samsung’s growth plans and how the coronavirus pandemic is impacting the industry.

    Contract Pharma (CP): What are some of the key drivers influencing the biopharma outsourcing market?

    Dr. Tae Han Kim:
    We are observing a significant impact from the current coronavirus pandemic on outsourcing decisions from biopharma companies. Originally the industry believed ‘Less is More,’ using fewer suppliers to maximize efficiency. However, the pandemic has exposed the risks of concentrating on single sources of supply. As a result, pharma/biotechs are revisiting their outsourcing strategy to implement more diversified multi-source channels as a countermeasure.

    In addition, due to the surging worldwide demand for COVID-19 vaccines and treatments, companies are looking for external development and manufacturing partners that can help accelerate their COVID-19 candidates to market. This presents us an opportunity to not only demonstrate our agility and execution excellence as a biologic CDMO, but also the privilege to work with the best biotech companies to make life-saving therapies more accessible to everyone suffering from this pandemic.

    CP: How can biopharma companies benefit from outsourcing their development and manufacturing?

    Dr. Kim:
    There are several benefits of outsourcing. First, it allows biotech companies to focus on more important areas of their business, such as clinical studies, regulatory affairs and sales/marketing. Second, outsourcing manufacturing to Samsung Biologics can also alleviate the large capital investments needed in plant construction and maintenance. And third, by outsourcing development services, clients can accelerate cell line development all the way to IND filing and related regulatory hurdles.

    CP: What are customers looking for from their service providers?

    Dr. Kim:
    Clients want high quality product at competitive cost, delivered on-time. Big pharmas are also looking for reliable second-source partners with innovative technology, capacity, and established track records of successful execution and quality. Emerging pharmas and biotechs look for partners with integrated service offerings that can propose tailored business terms and have the financial stability to ensure continuity of a campaign.

    CP: What are some of Samsung Biologics’ business highlights over the past year?

    Dr. Kim:
    We are the fastest growing company in the CDMO industry, and there is still very high growth momentum with our continued client-centric innovations.

    Samsung Biologics began as a large-scale contract manufacturing company to provide high quality, cost competitive service. Plant 1 has 30,000L, Plant 2 has 150,000L, and most recently Plant 3 was completed in 2017 with 12 X 15KL large scale manufacturing bioreactors and N-1 perfusion capability. Since then, we’ve added on 2 X 1KL stainless steel bioreactors and 2 X 1KL single-use bioreactors.

    At the same time, we recognized the growing need in the industry for development and testing support, and have integrated contract development services and analytical testing capabilities into our comprehensive end-to-end service offerings. Since the launch of our CDO services in late 2017, we’ve successfully partnered for over 50 development projects, invested in the Beacon platform, and developed our own proprietary cell line.

    Our partners range from Big Pharmas such as Roche, BMS, and UCB to emerging pharmas like TaiMed, Aprinoia and Vir Biotechnology.

    CP: What are the company’s expansion plans for the rest of 2020?

    Dr. Kim:
    In 2020, our plan is to open our first global site in San Francisco, through which we will be able to provide development services in closer proximity to our clients in the U.S. With the rise in DP demand, we’ll be investing in additional lyophilization capacity, and expanding our aseptic filling capabilities even further. Once all our drug substance (DS) capacity are fully contracted in Plant 1, 2 and 3, we’ll begin studying potential plant expansions.

    CP: How has the biopharma outsourcing landscape evolved over the past couple of years?

    Dr. Kim:
    In addition to the continued need for large scale commercial manufacturing capacity, the recent trend has also shown a surge in smaller-scale, niche market/orphan drug manufacturing demand. Accordingly, we’ve invested in smaller scale and single-use manufacturing facilities to address these needs.

    CP: How do you see the biopharma outsourcing landscape developing over the next several years? What impact will this have on the industry?

    Dr. Kim:
    Due to the high demand to treat illnesses such as Alzheimer’s Disease and novel viruses like COVID-19, the need for large scale manufacturing remains high. As more Big Pharmas diversify sources of product supply, they will have to choose more outsourcing options—a very positive outlook from Samsung Biologics’ point of view.

    CP: What are the greatest challenges and/or obstacles in today’s biopharma outsourcing market?

    Dr. Kim:
    While the biopharma industry has had a long history, aging facilities is also definitely one of the issues in the market. Many outsourcing companies have outdated machinery and facilities which cannot accommodate up-to-date bioprocesses and technologies. And it will cost significant capital investments and time to update or renovate them. Samsung Biologics however, has the flexibility of multiple plants and capability to build and validate the most modern cGMP facilities at a rate 40% faster than our competition, allowing us to keep our facilities up-to-date.

    CP: What has been Samsung Biologics’ response to the coronavirus pandemic?

    Dr. Kim:
    Samsung Biologics been taking very proactive measures to the COVID-19 outbreak, even before it began impacting the majority of the world outside China and South Korea. We’ve been operating under our Business Continuity Plan to ensure a stable supply chain and operations for uninterrupted services to our clients. Internally, our COVID-19 response team has been closely managing our employee health and safety around the clock, and we are fortunate to report we have had no employee cases confirmed to date.
    Additionally, in light of global travel restrictions and social distancing, we have made it possible for our clients to conduct audits and due diligence activities in real time remotely with secure and innovative technology. We’ve packaged this digital platform as “Samsung Biologics Live” which is now available along with other communication resources on our COVID-19 Client Resources website.

    CP: How do you see the pandemic impacting the biopharma supply chain?

    Dr. Kim:
    For the few less well-known suppliers, this could serve as an opportunity as companies seek out alternative vendors in case the main vendor is unable to supply the required materials on time. Internally at Samsung Biologics, we have established a supply chain management COVID-19 war room to actively monitor our global supply chain for any potential disruption to our raw materials and service providers. Our diligent efforts in this area have ensured our ability to manufacture and ship our clients’ drugs on schedule without issues of any kind. 
    Related Searches
    • Biologics, Proteins, Vaccines

    Related Features

    • Biologics, Proteins, Vaccines
      The Future of Biologics: Accelerating Production, Reducing Costs

      The Future of Biologics: Accelerating Production, Reducing Costs

      Yeast-based gene expression offers pharma the yield and efficiencies it needs to make pandemic-stopping vaccines faster and more economical.
      Mark Emalfarb, Dyadic 01.27.21

    • Biologics, Proteins, Vaccines | Regulatory Affairs
      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

      A look at EUA standards and approvals, unavoidable pitfalls, Operation Warp Speed, FDA’s use of Real-World Evidence, and a slow return to “normalcy.”
      Chad Landmon, Michelle Divelbiss and Alex Alfano, Attorneys - Axinn, Veltrop & Harkrider LLP 01.27.21

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Biologics, Proteins, Vaccines
      CAR-T Cell Therapy in Clinical Trials

      CAR-T Cell Therapy in Clinical Trials

      The importance of CAR-T cell therapy in clinical trials: the industry’s evolving, maturing focus
      Panteli Theocharous, Cell and Gene Therapy Strategy Lead, PPD 06.04.20


    • Biologics, Proteins, Vaccines
      Cell Therapy Manufacturing

      Cell Therapy Manufacturing

      Addressing the growing pains in cell therapy manufacturing
      Dr. Alessandra De Riva, Director of Process Development, Mogrify Ltd. 06.04.20

    • Biologics, Proteins, Vaccines
      The New Wave of Innovation

      The New Wave of Innovation

      Cell and gene therapies represent the new wave of innovation in the life sciences industry
      Tim Wright, Editor, Contract Pharma 06.04.20

    • Biologics, Proteins, Vaccines
      Covid 19: Impact on Bioprocessing and Outsourcing

      Covid 19: Impact on Bioprocessing and Outsourcing

      Outsourcing of biologics is increasing due to Covid-19, but what will change in the long-run?
      Ronald A. Rader & Eric S. Langer, BioPlan Associates 05.05.20


    • Biologics, Proteins, Vaccines
      The Evolution of the ADC Manufacturer

      The Evolution of the ADC Manufacturer

      How CMDOs can rise to the occasion
      Lisa McDermott and Jyothi Swamy, MilliporeSigma 04.01.20

    • Biologics, Proteins, Vaccines
      Biopharma Contract Manufacturing Pricing Analysis

      Biopharma Contract Manufacturing Pricing Analysis

      Expect increased prices over the next two years, but at slightly lower than historical trends
      William Downey, HighTech Business Decisions 01.28.20

    • Biologics, Proteins, Vaccines | Parenterals
      A Changing Healthcare Landscape

      A Changing Healthcare Landscape

      Navigating the road ahead with a focus towards patient centricity
      Peter Soelkner, Vetter Pharma International GmbH 01.28.20


    • Biologics, Proteins, Vaccines
      Regenerative Medicine: Overcoming the supply chain challenges

      Regenerative Medicine: Overcoming the supply chain challenges

      Accomplishing the goal of widespread use of regenerative medicine doesn’t come without its challenges.
      Rich Quelch, Global Head of Marketing, Origin 11.20.19

    • Biologics, Proteins, Vaccines
      Challenges and Opportunities in Vaccines Drug Development

      Challenges and Opportunities in Vaccines Drug Development

      As the uptake in vaccines continues to fall, the general public needs to be better informed.
      Adrian Wildfire, Scientific Director, SGS Life Sciences 11.20.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • ICON Acquires Medpass
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Danone Adds to Plant-Based Portfolio with Acquisition of Follow Your Heart Brand
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Christie Brinkley Joins SBLA Beauty
    Madison Reed Raises $52 Million in Financing Round
    The Estée Lauder Companies Closes Becca Cosmetics
    Happi

    Latest Breaking News From Happi

    MAC Cosmetics Launches Foundation
    ACI Unveils New Online Resources
    Sales More Than Double at Madison Reed
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    S-OneLP adds to growing team
    Avery Dennison expands automotive portfolio
    Amberley Labels turns to Kurz for embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    H&V Announces Price Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    SeaSpine Begins Limited Launch of WaveForm TA (TLIF Articulating) 3D-Printed Interbody
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login